This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (61)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Bacterial Infections  • Neurology  • Meningitis  • Public Health, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Nancy Rosenstein, MD; Orin Levine, PhD; Jeffery P. Taylor, MPH; Deborah Evans; Brian D. Plikaytis, MS; Jay D. Wenger, MD; Bradley A. Perkins, MD

JAMA. 1998;279:435-439.

Context.— Use of the quadrivalent meningococcal vaccine for control of outbreaks has increased in recent years, but the efficacy of meningococcal vaccine during mass vaccination campaigns in US civilian populations has not been assessed.

Objectives.— To evaluate the efficacy of the quadrivalent meningococcal vaccine against serogroup C meningococcal disease in a community outbreak setting and to evaluate potentially modifiable barriers to vaccination in an area with persistent meningococcal disease following immunization.

Design.— Matched case-control study of vaccine efficacy using cases of serogroup C meningococcal disease in persons eligible for vaccination during mass vaccination campaigns. Control patients were matched by neighborhood and age. The control group was used to identify possible barriers to vaccination.

Setting.— Gregg County, Texas, population 106076, from 1993 to 1995.

Participants.— A total of 17 case patients with serogroup C meningococcal disease eligible for vaccine and 84 control patients.

Main Outcome Measures.— Vaccine efficacy and risk factors associated with nonvaccination.

Results.— Vaccine efficacy among 2- to 29-year-olds was 85% (95% confidence interval, 27%-97%) and did not change in bivariate analyses with other risk factors that were significant in univariate analysis. Among control patients, older age was strongly associated with nonvaccination; vaccination rates for 2- to 4-year-olds, 5- to 18-year-olds, and 19- to 29-year-olds were 67%, 48%, and 20%, respectively (²for linear trend, P=.01).

Conclusions.— The meningococcal polysaccharide vaccine was effective against serogroup C meningococcal disease in this community outbreak. Although specific barriers to vaccination were not identified, older age was a risk factor for nonvaccination in the target population of 2- to 29-year-olds. In future outbreaks, emphasis should be placed on achieving high vaccination coverage, with special efforts to vaccinate young adults.

From the Childhood and Respiratory Diseases Branch (Drs Rosenstein, Levine, Wenger, and Perkins) and Biostatistics and Information Management Branch (Mr Plikaytis), Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Ga; and Infectious Disease Epidemiology and Surveillance Division, Texas Department of Health, Austin (Mr Taylor) and Tyler (Ms Evans).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Meningococcal Disease and Public Health Practice: A Complicated Road Map
Kristine A. Moore and Michael T. Osterholm
JAMA. 1998;279(6):472-473.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Nervous System Infections and Catheter Infections
Karam
ACCP Crit Care Med Brd Rev 2009;20:41-74.
FULL TEXT  

Prospects for Vaccine Prevention of Meningococcal Infection
Harrison
Clin. Microbiol. Rev. 2006;19:142-164.
ABSTRACT | FULL TEXT  

Prevention and Control of Meningococcal Disease: Recommendations for Use of Meningococcal Vaccines in Pediatric Patients
Committee on Infectious Diseases
Pediatrics 2005;116:496-505.
ABSTRACT | FULL TEXT  

Meningococcal Conjugate Vaccine in Adolescents and Children
Pichichero
CLIN PEDIATR 2005;44:479-489.
ABSTRACT  

Immunization of Female Mice with Glycoconjugates Protects Their Offspring against Encapsulated Bacteria
Richter et al.
Infect. Immun. 2004;72:187-195.
ABSTRACT | FULL TEXT  

Age-Related Disparity in Functional Activities of Human Group C Serum Anticapsular Antibodies Elicited by Meningococcal Polysaccharide Vaccine
Harris et al.
Infect. Immun. 2003;71:275-286.
ABSTRACT | FULL TEXT  

Sequence Diversity of Neisseria meningitidis 16S rRNA Genes and Use of 16S rRNA Gene Sequencing as a Molecular Subtyping Tool
Sacchi et al.
J. Clin. Microbiol. 2002;40:4520-4527.
ABSTRACT | FULL TEXT  

Invasive Meningococcal Disease in Adolescents and Young Adults
Harrison et al.
JAMA 2001;286:694-699.
ABSTRACT | FULL TEXT  

Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation
Skull et al.
Int J Epidemiol 2001;30:571-578.
ABSTRACT | FULL TEXT  

Meningococcal Disease
Rosenstein et al.
NEJM 2001;344:1378-1388.
FULL TEXT  

Dramatic decline of serogroup C meningococcal disease incidence in Catalonia (Spain) 24 months after a mass vaccination programme of children and young people
Salleras et al.
J. Epidemiol. Community Health 2001;55:283-287.
ABSTRACT | FULL TEXT  

Effectiveness of a Mass Immunization Campaign Against Serogroup C Meningococcal Disease in Quebec
De Wals et al.
JAMA 2001;285:177-181.
ABSTRACT | FULL TEXT  

Evaluation of Pulsed-Field Gel Electrophoresis in Epidemiological Investigations of Meningococcal Disease Outbreaks Caused by Neisseria meningitidis Serogroup C
Popovic et al.
J. Clin. Microbiol. 2001;39:75-85.
ABSTRACT | FULL TEXT  

Meningococcal Disease Prevention and Control Strategies for Practice-Based Physicians (Addendum: Recommendations for College Students)
Committee on Infectious Diseases
Pediatrics 2000;106:1500-1504.
ABSTRACT | FULL TEXT  

New Opportunities for Prevention of Meningococcal Disease
Perkins
JAMA 2000;283:2842-2844.
FULL TEXT  

Update on Meningococcal Disease with Emphasis on Pathogenesis and Clinical Management
van Deuren et al.
Clin. Microbiol. Rev. 2000;13:144-166.
ABSTRACT | FULL TEXT  

Conservation and Accessibility of an Inner Core Lipopolysaccharide Epitope of Neisseria meningitidis
Plested et al.
Infect. Immun. 1999;67:5417-5426.
ABSTRACT | FULL TEXT  

Meningococcal Infection in College Students
Barton and Shulman
AAP Grand Rounds 1999;2:13-14.
FULL TEXT  

Risk of Meningococcal Infection in College Students
Harrison et al.
JAMA 1999;281:1906-1910.
ABSTRACT | FULL TEXT  

Humoral Immune Responses to Neisseria meningitidis in Children
Pollard et al.
Infect. Immun. 1999;67:2441-2451.
ABSTRACT | FULL TEXT  

Immunogenicity of 2 Serogroup B Outer-Membrane Protein Meningococcal Vaccines: A Randomized Controlled Trial in Chile
Tappero et al.
JAMA 1999;281:1520-1527.
ABSTRACT | FULL TEXT  

The Efficacy of Meningococcal Vaccine
JWatch Infect. Diseases 1998;1998:11-11.
FULL TEXT  

Meningococcal Vaccine Use Validated
Journal Watch Dermatology 1998;1998:14-14.
FULL TEXT  

Meningococcal Vaccine Use Validated
JWatch General 1998;1998:3-3.
FULL TEXT  

Meningococcal Disease and Public Health Practice: A Complicated Road Map
Moore and Osterholm
JAMA 1998;279:472-473.
FULL TEXT